Therefore, this work developed a novel biomaterial for improving the immune stimulation effect of EBRT and RNT, and discovered some differences in cGAS-STING pathway activation between EBRT and RNT, providing some reference and strategic design for the implementation of clinical tumor RT. The gene discussed is STING1; the disease is neoplasm.